Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Analysis of Short-term (Operating) Activity Ratios 

Microsoft Excel

Short-term Activity Ratios (Summary)

Merck & Co. Inc., short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Turnover Ratios
Inventory turnover 2.49 2.54 2.95 2.29 2.45
Receivables turnover 6.24 5.81 6.27 5.28 6.11
Payables turnover 3.72 4.11 4.08 2.96 3.37
Working capital turnover 6.19 9.29 5.16 7.62 109.83
Average No. Days
Average inventory processing period 147 144 124 159 149
Add: Average receivable collection period 58 63 58 69 60
Operating cycle 205 207 182 228 209
Less: Average payables payment period 98 89 89 123 108
Cash conversion cycle 107 118 93 105 101

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Inventory Turnover
The inventory turnover ratio experienced fluctuations over the observed period. It began at 2.45 in 2020, slightly declined to 2.29 in 2021, reached a peak of 2.95 in 2022, before decreasing again to 2.54 in 2023 and further to 2.49 in 2024. This indicates some variability in how efficiently inventory is managed, with the highest efficiency noted in 2022.
Receivables Turnover
This ratio showed a dip from 6.11 in 2020 to 5.28 in 2021, then recovered to 6.27 in 2022. It slightly decreased to 5.81 in 2023, followed by a rise to 6.24 in 2024. These variations suggest fluctuations in the company's effectiveness in collecting receivables, with generally strong performance in the latter years.
Payables Turnover
Payables turnover decreased from 3.37 in 2020 to 2.96 in 2021, then significantly increased to 4.08 in 2022 and stabilized around 4.11 in 2023 before declining to 3.72 in 2024. This pattern indicates changes in payment practices to suppliers, with a notable acceleration in 2022 and 2023 followed by a slight slowdown.
Working Capital Turnover
A pronounced decline was observed from 109.83 in 2020 to 7.62 in 2021, continuing downward to 5.16 in 2022. A rebound to 9.29 occurred in 2023, followed by another decline to 6.19 in 2024. The sharp drop starting in 2021 suggests a significant change in either sales or working capital management, with ongoing volatility in later periods.
Average Inventory Processing Period
The number of days to process inventory increased from 149 days in 2020 to 159 days in 2021, then decreased noticeably to 124 days in 2022. It rose again to 144 days in 2023 and slightly increased further to 147 days in 2024. This cyclical pattern implies variability in inventory turnover speed, with the shortest period in 2022.
Average Receivable Collection Period
The collection period lengthened from 60 days in 2020 to 69 days in 2021, then shortened to 58 days in 2022. It rose again to 63 days in 2023 and returned to 58 days in 2024. The data indicate an oscillating trend in how quickly the company collects payments from customers.
Operating Cycle
The operating cycle extended from 209 days in 2020 to 228 days in 2021, then shortened significantly to 182 days in 2022. It increased to 207 days in 2023 and remained relatively stable at 205 days in 2024. These fluctuations reflect changes in combined inventory and receivable management efficiency over the years.
Average Payables Payment Period
The payment period to suppliers grew from 108 days in 2020 to 123 days in 2021, then shortened sharply to 89 days in 2022 and stabilized around that value in 2023. There was a slight increase to 98 days in 2024. This suggests variations in payment policy, with the company taking longer to pay in early years and then accelerating payments before slightly extending them again.
Cash Conversion Cycle
The cash conversion cycle, indicating net time to convert inputs into cash, increased from 101 days in 2020 to 105 days in 2021, then decreased to 93 days in 2022. It rose considerably to 118 days in 2023 and then moderately declined to 107 days in 2024. Overall, despite some improvement in 2022, the longer cycle in recent years could suggest reduced liquidity efficiency.

Turnover Ratios


Average No. Days


Inventory Turnover

Merck & Co. Inc., inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Cost of sales 15,193 16,126 17,411 13,626 15,485
Inventories, excludes inventories classified in Other assets 6,109 6,358 5,911 5,953 6,310
Short-term Activity Ratio
Inventory turnover1 2.49 2.54 2.95 2.29 2.45
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 4.04 4.98 4.87 5.58 4.65
Amgen Inc. 1.84 0.89 1.30 1.58 1.58
Bristol-Myers Squibb Co. 5.46 4.02 4.33 4.74 5.68
Danaher Corp. 4.15 3.80 4.03 4.16 4.28
Eli Lilly & Co. 1.11 1.23 1.54 1.88 1.38
Gilead Sciences Inc. 3.66 3.64 3.75 4.08 2.72
Johnson & Johnson 2.21 2.37 2.49 2.87 3.04
Pfizer Inc. 1.65 2.45 3.82 3.40 1.08
Regeneron Pharmaceuticals Inc. 0.64 0.70 0.65 1.25 0.58
Thermo Fisher Scientific Inc. 5.06 5.06 4.60 3.88 4.02
Vertex Pharmaceuticals Inc. 1.27 1.71 2.35 2.56 2.62
Inventory Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 2.46 2.55 3.06 3.11 2.63
Inventory Turnover, Industry
Health Care 7.56 7.36 7.85 7.90 6.97

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Inventory turnover = Cost of sales ÷ Inventories, excludes inventories classified in Other assets
= 15,193 ÷ 6,109 = 2.49

2 Click competitor name to see calculations.


Cost of Sales
The cost of sales exhibited a fluctuating trend over the five-year period. It decreased from $15,485 million in 2020 to $13,626 million in 2021, indicating a reduction in production or procurement expenses during that year. However, this was followed by a sharp increase to $17,411 million in 2022, the highest within the period. Subsequently, costs decreased again in 2023 to $16,126 million, continuing the downward movement in 2024 to $15,193 million. Overall, the cost of sales shows variability with a peak in 2022, suggesting possible volatility in supply chain costs or production volumes.
Inventories
The inventory levels remained relatively stable, with minor fluctuations over the five years. Beginning at $6,310 million in 2020, inventories slightly decreased to $5,953 million in 2021 and further to $5,911 million in 2022. A recovery to $6,358 million occurred in 2023, followed by a modest decline to $6,109 million in 2024. This pattern indicates controlled inventory management without significant buildup or reduction, maintaining a consistent inventory base.
Inventory Turnover
Inventory turnover ratios fluctuated within a narrow range, reflecting changes in inventory efficiency. The ratio decreased from 2.45 in 2020 to 2.29 in 2021, implying slower inventory movement relative to cost of sales. This was followed by a notable increase to 2.95 in 2022, indicating improved turnover and possibly stronger sales or better inventory management. The ratio then declined to 2.54 in 2023 and slightly further to 2.49 in 2024. These movements suggest variable inventory management efficiency, with a peak performance in 2022 before moving back towards the initial levels.

Receivables Turnover

Merck & Co. Inc., receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Sales 64,168 60,115 59,283 48,704 47,994
Accounts receivable, net of allowance for doubtful accounts 10,278 10,349 9,450 9,230 7,851
Short-term Activity Ratio
Receivables turnover1 6.24 5.81 6.27 5.28 6.11
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 5.16 4.87 5.16 5.63 5.19
Amgen Inc. 4.72 3.70 4.46 4.96 5.36
Bristol-Myers Squibb Co. 5.19 4.93 5.48 5.65 5.72
Danaher Corp. 6.75 6.09 6.40 6.36 5.51
Eli Lilly & Co. 4.09 3.75 4.14 4.24 4.18
Gilead Sciences Inc. 6.47 5.78 5.65 6.01 4.98
Johnson & Johnson 5.98 5.73 5.88 6.14 6.08
Pfizer Inc. 5.55 5.33 9.24 7.16 5.38
Regeneron Pharmaceuticals Inc. 2.29 2.31 2.28 2.66 2.07
Thermo Fisher Scientific Inc. 5.23 5.21 5.53 4.92 5.61
Vertex Pharmaceuticals Inc. 6.85 6.31 6.19 6.66 7.01
Receivables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.26 4.96 5.76 5.54 5.34
Receivables Turnover, Industry
Health Care 7.97 7.66 8.22 8.00 7.88

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Receivables turnover = Sales ÷ Accounts receivable, net of allowance for doubtful accounts
= 64,168 ÷ 10,278 = 6.24

2 Click competitor name to see calculations.


Sales
The sales figures show a consistent upward trajectory over the five-year period. Starting at $47,994 million in 2020, sales increased modestly to $48,704 million in 2021. This was followed by a significant rise to $59,283 million in 2022. The upward trend continued with sales reaching $60,115 million in 2023, and further growing to $64,168 million by 2024. Overall, this indicates steady revenue growth, with particularly strong performance between 2021 and 2022.
Accounts Receivable, Net of Allowance for Doubtful Accounts
The net accounts receivable balances grew from $7,851 million in 2020 to $10,278 million in 2024. The largest year-over-year increase occurred between 2020 and 2021, rising by approximately $1,379 million. Growth in receivables continued through 2023, reaching $10,349 million, before slightly decreasing in 2024 to $10,278 million. This slight decline in the final year may reflect improved collection or changes in credit policy. Overall, accounts receivable expanded in line with sales growth, suggesting an increasing volume of credit extended to customers.
Receivables Turnover
The receivables turnover ratio experienced fluctuations during the period. It started at 6.11 in 2020, declining to 5.28 in 2021, which suggests slower collection efficiency during that year. The ratio improved markedly to 6.27 in 2022, indicating faster collection relative to receivables outstanding. A moderate drop to 5.81 was observed in 2023, followed by a recovery to 6.24 in 2024. These oscillations imply variability in collection practices or customer payment behavior, although the general trend shows a return to turnover levels similar to those at the beginning of the period.

Payables Turnover

Merck & Co. Inc., payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Cost of sales 15,193 16,126 17,411 13,626 15,485
Trade accounts payable 4,079 3,922 4,264 4,609 4,594
Short-term Activity Ratio
Payables turnover1 3.72 4.11 4.08 2.96 3.37
Benchmarks
Payables Turnover, Competitors2
AbbVie Inc. 5.74 5.54 5.94 6.05 6.76
Amgen Inc. 6.74 5.32 4.08 4.72 4.33
Bristol-Myers Squibb Co. 3.88 3.28 3.33 3.37 4.34
Danaher Corp. 5.52 5.58 5.45 4.48 4.79
Eli Lilly & Co. 2.61 2.73 3.43 4.38 3.41
Gilead Sciences Inc. 7.50 11.81 6.25 9.36 5.42
Johnson & Johnson 2.66 2.76 2.66 2.70 2.99
Pfizer Inc. 3.17 3.72 5.04 5.53 2.02
Regeneron Pharmaceuticals Inc. 2.50 2.99 2.65 4.32 2.36
Thermo Fisher Scientific Inc. 8.18 8.97 7.67 6.83 7.45
Vertex Pharmaceuticals Inc. 3.71 3.46 3.55 4.64 4.75
Payables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.08 4.25 4.28 4.23 3.86
Payables Turnover, Industry
Health Care 6.10 5.97 5.79 5.84 5.57

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Payables turnover = Cost of sales ÷ Trade accounts payable
= 15,193 ÷ 4,079 = 3.72

2 Click competitor name to see calculations.


Cost of Sales
The cost of sales exhibited notable fluctuations over the five-year period. Starting at $15,485 million in 2020, it declined to $13,626 million in 2021, followed by a significant increase to $17,411 million in 2022. Subsequently, it decreased to $16,126 million in 2023 and further to $15,193 million in 2024. This pattern suggests volatility in either production costs or sales volumes, with the peak value in 2022 indicating a possible period of increased operational activity or higher input costs.
Trade Accounts Payable
Trade accounts payable showed a generally downward trend from $4,594 million in 2020 to $3,922 million in 2023, but saw a slight increase to $4,079 million in 2024. The initial decline may reflect improved payment terms or reduced outstanding liabilities, while the uptick in the last year could indicate an increase in purchases on credit or delayed payments.
Payables Turnover Ratio
The payables turnover ratio, which measures how quickly the company pays off its suppliers, started at 3.37 in 2020, decreased to 2.96 in 2021, then rose sharply to 4.08 in 2022 and slightly increased to 4.11 in 2023 before falling to 3.72 in 2024. The increase in 2022 and 2023 implies faster payments to creditors during these years, possibly reflecting improved liquidity or supplier agreements. The decline in 2024 suggests a slight slowdown in payment speed, though it remains above the levels seen in 2020 and 2021.

Working Capital Turnover

Merck & Co. Inc., working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Current assets 38,782 32,168 35,722 30,266 27,764
Less: Current liabilities 28,420 25,694 24,239 23,872 27,327
Working capital 10,362 6,474 11,483 6,394 437
 
Sales 64,168 60,115 59,283 48,704 47,994
Short-term Activity Ratio
Working capital turnover1 6.19 9.29 5.16 7.62 109.83
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc. 5.40 2.25 3.82 3.37 2.55
Bristol-Myers Squibb Co. 7.79 4.60 8.30 3.95 3.72
Danaher Corp. 8.85 4.22 4.20 8.40 3.48
Eli Lilly & Co. 10.32 31.84 8.33 4.93
Gilead Sciences Inc. 3.99 5.61 8.42 8.54 5.30
Johnson & Johnson 15.94 11.81 5.95 9.44
Pfizer Inc. 8.64 11.09 4.83 4.67
Regeneron Pharmaceuticals Inc. 0.97 0.82 0.96 1.59 1.20
Thermo Fisher Scientific Inc. 4.87 4.05 5.46 5.87 2.76
Vertex Pharmaceuticals Inc. 1.83 0.93 0.85 1.02 0.99
Working Capital Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 7.86 6.68 7.25 5.87 5.34
Working Capital Turnover, Industry
Health Care 12.35 10.99 11.30 8.57 8.40

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Working capital turnover = Sales ÷ Working capital
= 64,168 ÷ 10,362 = 6.19

2 Click competitor name to see calculations.


Working Capital
Working capital shows a significant increase from 437 million US dollars in 2020 to 11,483 million US dollars in 2022. However, it declines notably to 6,474 million in 2023 before rising again to 10,362 million in 2024. This indicates an overall upward trend with some volatility in the intermediate years.
Sales
Sales exhibit a consistent upward trajectory throughout the period. Starting at 47,994 million US dollars in 2020, sales increase steadily each year, reaching 64,168 million in 2024. This reflects sustained growth in revenue over the five-year span.
Working Capital Turnover
Working capital turnover, calculated as the ratio of sales to working capital, declines sharply from 109.83 in 2020 to 5.16 in 2022. It then rises to 9.29 in 2023 before falling again to 6.19 in 2024. The initial sharp decline indicates that working capital grew at a faster pace than sales in the early years, reducing the efficiency of capital use, while the subsequent fluctuations suggest some variability in operational efficiency.
Overall Analysis
The data reveals a scenario of rapidly expanding working capital alongside steadily increasing sales. The disproportionate growth rates in the early years lead to a significant drop in working capital turnover, implying less efficient use of working capital relative to sales. Despite some recovery in turnover ratios later, the levels remain considerably lower than the initial year, highlighting ongoing challenges in optimizing working capital use in relation to sales growth.

Average Inventory Processing Period

Merck & Co. Inc., average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Inventory turnover 2.49 2.54 2.95 2.29 2.45
Short-term Activity Ratio (no. days)
Average inventory processing period1 147 144 124 159 149
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 90 73 75 65 79
Amgen Inc. 199 411 281 231 231
Bristol-Myers Squibb Co. 67 91 84 77 64
Danaher Corp. 88 96 91 88 85
Eli Lilly & Co. 329 298 237 194 265
Gilead Sciences Inc. 100 100 97 89 134
Johnson & Johnson 165 154 147 127 120
Pfizer Inc. 222 149 95 107 338
Regeneron Pharmaceuticals Inc. 572 519 562 292 625
Thermo Fisher Scientific Inc. 72 72 79 94 91
Vertex Pharmaceuticals Inc. 287 214 156 143 139
Average Inventory Processing Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 149 143 119 117 139
Average Inventory Processing Period, Industry
Health Care 48 50 46 46 52

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.49 = 147

2 Click competitor name to see calculations.


The financial data reveals notable trends in inventory management over the five-year period. The inventory turnover ratio exhibits fluctuations rather than a consistent trajectory. Initially, there is a decline from 2.45 in 2020 to 2.29 in 2021, indicating a reduced rate of inventory cycling. Subsequently, the ratio rises sharply to 2.95 in 2022, suggesting a significant improvement in the efficiency of inventory usage within that year. However, this increase does not sustain, as the ratio declines again to 2.54 in 2023 and slightly further to 2.49 in 2024, indicating some easing of inventory turnover efficiency.*

Conversely, the average inventory processing period, measured in days, displays an inverse and somewhat corresponding pattern to the inventory turnover ratio. The number of days increases from 149 in 2020 to 159 in 2021, signaling slower inventory processing. This period then shortens considerably to 124 days in 2022, a sign of improved inventory management speed during that year. The processing period extends again in the subsequent years, reaching 144 days in 2023 and slightly increasing to 147 days in 2024, aligning with the trend of a decreasing turnover ratio in those years.*

Overall, the data suggests that inventory management experienced a peak of efficiency in 2022, as indicated by the highest turnover ratio and shortest processing period. Before and after this peak, the trends point to somewhat less efficient inventory handling. The slight deterioration in turnover and processing duration in the latter years may warrant attention to understand the operational or market factors influencing these changes.


Average Receivable Collection Period

Merck & Co. Inc., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Receivables turnover 6.24 5.81 6.27 5.28 6.11
Short-term Activity Ratio (no. days)
Average receivable collection period1 58 63 58 69 60
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 71 75 71 65 70
Amgen Inc. 77 99 82 74 68
Bristol-Myers Squibb Co. 70 74 67 65 64
Danaher Corp. 54 60 57 57 66
Eli Lilly & Co. 89 97 88 86 87
Gilead Sciences Inc. 56 63 65 61 73
Johnson & Johnson 61 64 62 59 60
Pfizer Inc. 66 69 40 51 68
Regeneron Pharmaceuticals Inc. 160 158 160 137 177
Thermo Fisher Scientific Inc. 70 70 66 74 65
Vertex Pharmaceuticals Inc. 53 58 59 55 52
Average Receivable Collection Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 69 74 63 66 68
Average Receivable Collection Period, Industry
Health Care 46 48 44 46 46

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.24 = 58

2 Click competitor name to see calculations.


Receivables Turnover Ratio
The receivables turnover ratio demonstrates fluctuations across the five-year period. It decreased from 6.11 in 2020 to 5.28 in 2021, indicating a slower collection of receivables. This was followed by an improvement in 2022, rising to 6.27, which suggests enhanced efficiency in collecting outstanding credit. The ratio declined again to 5.81 in 2023, before recovering to 6.24 in 2024, nearing the 2020 level. Overall, the pattern reflects variability but generally maintains a level around 6, implying periodic changes in credit management or sales terms.
Average Receivable Collection Period
The average receivable collection period inversely mirrors the turnover ratio trends. The collection period lengthened from 60 days in 2020 to 69 days in 2021, indicating slower cash inflows from receivables. It then shortened considerably to 58 days in 2022, which aligns with the increased turnover ratio for that year. In 2023, the collection period extended again to 63 days, before reducing back to 58 days in 2024. These changes demonstrate alternating effectiveness in receivables management, with the collection period typically oscillating between just under two months and slightly over two months.
Overall Insights
The fluctuations in both the receivables turnover ratio and the average collection period suggest periodic adjustments or challenges in credit policies, customer payment behavior, or operational efficiency. The company's ability to return to shorter collection periods and higher turnover ratios by 2024 indicates active efforts to optimize cash flow management. Maintaining a collection period near 58 days and a turnover ratio around 6 suggests a stable but moderately paced receivables cycle over the reported timeframe.

Operating Cycle

Merck & Co. Inc., operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Average inventory processing period 147 144 124 159 149
Average receivable collection period 58 63 58 69 60
Short-term Activity Ratio
Operating cycle1 205 207 182 228 209
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 161 148 146 130 149
Amgen Inc. 276 510 363 305 299
Bristol-Myers Squibb Co. 137 165 151 142 128
Danaher Corp. 142 156 148 145 151
Eli Lilly & Co. 418 395 325 280 352
Gilead Sciences Inc. 156 163 162 150 207
Johnson & Johnson 226 218 209 186 180
Pfizer Inc. 288 218 135 158 406
Regeneron Pharmaceuticals Inc. 732 677 722 429 802
Thermo Fisher Scientific Inc. 142 142 145 168 156
Vertex Pharmaceuticals Inc. 340 272 215 198 191
Operating Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences 218 217 182 183 207
Operating Cycle, Industry
Health Care 94 98 90 92 98

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 147 + 58 = 205

2 Click competitor name to see calculations.


Average Inventory Processing Period
The average inventory processing period fluctuated over the five-year period. It increased from 149 days in 2020 to 159 days in 2021, before decreasing significantly to 124 days in 2022. Subsequently, it rose again to 144 days in 2023 and slightly increased to 147 days in 2024. This indicates some variability in inventory management efficiency, with the shortest processing time observed in 2022.
Average Receivable Collection Period
The average receivable collection period experienced minor fluctuations. It increased from 60 days in 2020 to 69 days in 2021, followed by a drop to 58 days in 2022. The period rose slightly to 63 days in 2023 and then returned to 58 days in 2024. Overall, the collection period remained relatively stable around the high 50s to high 60s range, suggesting consistent receivables management.
Operating Cycle
The operating cycle tended to mirror the combined dynamics of the inventory processing and receivable collection periods. It increased from 209 days in 2020 to 228 days in 2021, then sharply decreased to 182 days in 2022. This was followed by an increase to 207 days in 2023 and a slight decline to 205 days in 2024. The trend shows responsiveness to changes in working capital management, with the shortest operating cycle in 2022 indicating improved efficiency during that year.

Average Payables Payment Period

Merck & Co. Inc., average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Payables turnover 3.72 4.11 4.08 2.96 3.37
Short-term Activity Ratio (no. days)
Average payables payment period1 98 89 89 123 108
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
AbbVie Inc. 64 66 61 60 54
Amgen Inc. 54 69 90 77 84
Bristol-Myers Squibb Co. 94 111 109 108 84
Danaher Corp. 66 65 67 82 76
Eli Lilly & Co. 140 134 106 83 107
Gilead Sciences Inc. 49 31 58 39 67
Johnson & Johnson 137 132 137 135 122
Pfizer Inc. 115 98 72 66 181
Regeneron Pharmaceuticals Inc. 146 122 138 84 155
Thermo Fisher Scientific Inc. 45 41 48 53 49
Vertex Pharmaceuticals Inc. 98 106 103 79 77
Average Payables Payment Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 90 86 85 86 95
Average Payables Payment Period, Industry
Health Care 60 61 63 63 66

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.72 = 98

2 Click competitor name to see calculations.


Payables Turnover
The payables turnover ratio exhibited fluctuations over the analyzed periods. Starting at 3.37 in 2020, it decreased to 2.96 in 2021, indicating a slower rate of paying off suppliers. This was followed by a notable increase to 4.08 in 2022, suggesting a faster payment cycle. The ratio remained relatively stable in 2023 at 4.11, before slightly declining to 3.72 in 2024. Overall, the trend reflects variability in payment efficiency but an improvement from the 2021 low.
Average Payables Payment Period
The average duration to settle payables shows an inverse relationship to the payables turnover ratio. Initially, the payment period increased from 108 days in 2020 to 123 days in 2021, signaling slower payments. Subsequently, it decreased significantly to 89 days in both 2022 and 2023, indicating accelerated payments. In 2024, the payment period extended again to 98 days, although it remained below the 2020 and 2021 figures. This suggests a move toward more prompt payment practices after 2021, with some moderation in the latest year.
Overall Insights
From 2020 to 2024, the company's payables management reflects a dynamic pattern with a peak in extended payment periods in 2021, followed by a return to faster payment cycles in subsequent years. The improvements in payables turnover and reductions in payment days from 2022 to 2023 indicate enhanced operational efficiency in managing liabilities, although the slight reversal in 2024 may imply adjustments in payment policies or supplier terms.

Cash Conversion Cycle

Merck & Co. Inc., cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data
Average inventory processing period 147 144 124 159 149
Average receivable collection period 58 63 58 69 60
Average payables payment period 98 89 89 123 108
Short-term Activity Ratio
Cash conversion cycle1 107 118 93 105 101
Benchmarks
Cash Conversion Cycle, Competitors2
AbbVie Inc. 97 82 85 70 95
Amgen Inc. 222 441 273 228 215
Bristol-Myers Squibb Co. 43 54 42 34 44
Danaher Corp. 76 91 81 63 75
Eli Lilly & Co. 278 261 219 197 245
Gilead Sciences Inc. 107 132 104 111 140
Johnson & Johnson 89 86 72 51 58
Pfizer Inc. 173 120 63 92 225
Regeneron Pharmaceuticals Inc. 586 555 584 345 647
Thermo Fisher Scientific Inc. 97 101 97 115 107
Vertex Pharmaceuticals Inc. 242 166 112 119 114
Cash Conversion Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences 128 131 97 97 112
Cash Conversion Cycle, Industry
Health Care 34 37 27 29 32

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 147 + 5898 = 107

2 Click competitor name to see calculations.


Average Inventory Processing Period
The average inventory processing period exhibited variability over the five-year span. It increased from 149 days at the end of 2020 to a peak of 159 days in 2021, followed by a notable decline to 124 days in 2022. Subsequently, it rose again to 144 days in 2023 and slightly increased further to 147 days by the end of 2024. This pattern indicates fluctuations in inventory management efficiency, with some improvement observed in 2022, though the period remained relatively high overall.
Average Receivable Collection Period
The receivable collection period exhibited moderate fluctuations. It increased from 60 days in 2020 to 69 days in 2021, suggesting a slower collection of receivables during that year. The period improved to 58 days in 2022, indicating faster collections, but then slightly slowed to 63 days in 2023 and improved again to 58 days in 2024. Overall, the trend indicates some variability but an ability to maintain collection periods close to the initial 2020 level by 2024.
Average Payables Payment Period
The payables payment period showed considerable variation. Beginning at 108 days in 2020, it increased to 123 days in 2021, implying a longer period to settle payments. However, it dropped sharply to 89 days in 2022 and remained steady at 89 days in 2023, before increasing to 98 days in 2024. This suggests a deliberate strategy to optimize payment timing, with a significant reduction in payment days after 2021 but a slight extension in the most recent year.
Cash Conversion Cycle
The cash conversion cycle demonstrated fluctuation throughout the period. Starting at 101 days in 2020, it rose slightly to 105 days in 2021, decreased to 93 days in 2022, then increased markedly to 118 days in 2023, before declining again to 107 days in 2024. These changes reflect the combined effects of inventory, receivables, and payables management, with the longest cash conversion cycle occurring in 2023, indicating greater capital tied up in operations during that year, followed by some improvement in 2024.